These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29964140)

  • 1. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis.
    Balsells E; Dagan R; Yildirim I; Gounder PP; Steens A; Muñoz-Almagro C; Mameli C; Kandasamy R; Givon Lavi N; Daprai L; van der Ende A; Trzciński K; Nzenze SA; Meiring S; Foster D; Bulkow LR; Rudolph K; Valero-Rello A; Ducker S; Vestrheim DF; von Gottberg A; Pelton SI; Zuccotti G; Pollard AJ; Sanders EAM; Campbell H; Madhi SA; Nair H; Kyaw MH
    J Infect; 2018 Nov; 77(5):368-378. PubMed ID: 29964140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.
    Balsells E; Guillot L; Nair H; Kyaw MH
    PLoS One; 2017; 12(5):e0177113. PubMed ID: 28486544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts' children to relatively low invasiveness.
    Yildirim I; Little BA; Finkelstein J; Lee G; Hanage WP; Shea K; Pelton SI; ;
    Vaccine; 2017 Jul; 35(32):4002-4009. PubMed ID: 28645717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Imöhl M
    PLoS One; 2015; 10(7):e0131494. PubMed ID: 26132078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children.
    Varon E; Cohen R; Béchet S; Doit C; Levy C
    Vaccine; 2015 Nov; 33(46):6178-85. PubMed ID: 26476365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children.
    Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC
    Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.
    Slotved HC; Dalby T; Hoffmann S
    Vaccine; 2016 Feb; 34(6):769-74. PubMed ID: 26772630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique.
    Massora S; Lessa FC; Moiane B; Pimenta FC; Mucavele H; Chaúque A; Cossa A; Verani JR; Tembe N; da Gloria Carvalho M; Muñoz-Almagro C; Sigaúque B
    Vaccine; 2019 Dec; 37(51):7470-7477. PubMed ID: 31575493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes.
    Slotved HC
    Hum Vaccin Immunother; 2016 Oct; 12(10):2670-2674. PubMed ID: 27322025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-depth analysis of pneumococcal serotypes in Belgian children (2015-2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease.
    Desmet S; Wouters I; Heirstraeten LV; Beutels P; Van Damme P; Malhotra-Kumar S; Maes P; Verhaegen J; Peetermans WE; Lagrou K; Theeten H
    Vaccine; 2021 Jan; 39(2):372-379. PubMed ID: 33308889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
    Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England.
    Southern J; Andrews N; Sandu P; Sheppard CL; Waight PA; Fry NK; Van Hoek AJ; Miller E
    PLoS One; 2018; 13(5):e0195799. PubMed ID: 29799839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease.
    Yildirim I; Hanage WP; Lipsitch M; Shea KM; Stevenson A; Finkelstein J; Huang SS; Lee GM; Kleinman K; Pelton SI
    Vaccine; 2010 Dec; 29(2):283-8. PubMed ID: 21029807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency.
    Løchen A; Croucher NJ; Anderson RM
    Sci Rep; 2020 Nov; 10(1):18977. PubMed ID: 33149149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands.
    Vissers M; Wijmenga-Monsuur AJ; Knol MJ; Badoux P; van Houten MA; van der Ende A; Sanders EAM; Rots NY
    PLoS One; 2018; 13(3):e0194823. PubMed ID: 29601605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.